Vendor, New Haven, CT
L2 Diagnostics LLC
UEI GKA7VH5LFR25, CAGE 43BA5
2 awards and $899,471 obligated between December 3, 2024 and July 22, 2026, 100% under full and open competition, against 6.0 offers on average where reported. 1 of the awards trace back to a SAM.gov solicitation on this site.
Industries
NAICS on the awards, by dollars.
How it wins
Awards by competition, set-aside and type.
| Full and Open Competition After Exclusion of Sources | 2 |
| Small Business Set Aside - Total | 2 |
| Definitive Contract | 2 |
Awards
Every award in the window, by dollars obligated.
| Contract | Awarding office | Described as | Obligated |
|---|---|---|---|
| 75N93025C00024Definitive Contract, July 28, 2025, Full and Open Competition After Exclusion of Sources, 9 offersSolicitation | National Institutes of Health NiaidNational Institutes of Health | Therapeutic Vaccine Platform to Boost Immune Responses in TuberculosisNAICS 541715, PSC AN11 | $599,471 |
| 75N93025C00004Definitive Contract, December 3, 2024, Full and Open Competition After Exclusion of Sources, 3 offers | National Institutes of Health NiaidNational Institutes of Health | Novel Diagnostic Biomarkers Discovery and Validation for Malaria SBIR Phase INAICS 541714, PSC AN12 | $300,000 |
- Places of performance
- Connecticut
- Product and service codes
- AN11 Health R&D Services; Health Care Services; Basic ResearchAN12 Health R&D Services; Health Care Services; Applied Research
- Transactions
- 5 across 2 awards